

35. (Amended) A pharmaceutical composition according to claim 4 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of said compound.

36. (Amended) A pharmaceutical composition according to claim 4 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of said compound.

REMARKS

Claims 1, 2, 4, 5 and 35-36 are now pending following entry of this Amendment. As required by 37 C.F.R. 1.121, a "marked-up" copy of the amendments to the claims is appended to this Amendment.

The objection to claims 5, 35 and 36 as being in improper form is rendered moot by the amendments to these claims presented herein.

REJECTIONS UNDER 35 USC §112, SECOND PARAGRAPH

The Examiner rejected claims 1, 2, 4, 5 and 35-36 as indefinite under §112, second paragraph because:

- 1) Commas or semicolons should be added after each compound listed in claims 1 and 2 and an "and" should be added before the last compound listed in claims 1 and 2; and
- 2) Sulfonyl is misspelled in several instances in claim 1.

3)

In response, Applicants respectfully submit that each of these rejections is rendered moot by the amendments to the claims presented herein

Accordingly, Applicants respectfully request withdrawal of the §112, second paragraph rejections.

OBVIOUSNESS-TYPE DOUBLE PATENTING REJECTION

Claims 1, 2, 4, 5, and 35-36 were provisionally rejected under the doctrine of obviousness-type double patenting as being unpatentable over claims 1,5, 13, 16-18, 22,, 23, 43-46, 49, 53, 55-57, 59, 63, 68-71, 89, 90, 93, 94, 98, 100-114, 116, and 118 of copending application 09/572,553. In response, Applicants note application 09/572, 553 issued as US patent 6,503,949 on January 7, 2003 and accordingly, respectfully submit a terminal disclaimer over this US patent to obviate this double patenting rejection. In submitting this terminal disclaimer, Applicants note that the "filing of a terminal disclaimer simply serves the statutory function of removing the rejection of double patenting and raises neither a presumption nor estoppel on the merits of the rejection". Quad Environmental

Technologies Corp. v. Union Sanitary District, 20 USPQ 2d 1392 (Fed. Cir. 1991).

REJECTIONS UNDER 35 USC §103

The Examiner provisionally rejected claims 1, 2, 4, 5 and 35-36 under §103 as obvious over copending application 09/572,553 (now US patent 6,503,949). The Examiner stated that based upon the earlier US filing date of the 09/572,553 application, it would constitute prior art under 35 U.S.C. 102 (e) if published or patented.

Applicants respectfully traverse this rejection.

Applicants note that application 09/572,553 issued as US patent 6,503,949 on January 7, 2003 and that the AIPA amended 35 U.S.C. 103 (c) to recite that effective November 29, 1999, subject matter which was prior art under 35 U.S.C. 103 via section 102(e) is now disqualified as prior art against the claimed invention if that subject matter and the claimed invention "were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person". See MPEP 706.02(l)(1).

As the present application was filed on November 16, 2001 (ie after November 29, 1999), this change to 35 U.S.C. 103 (c) applies to the present application.

Accordingly, the undersigned hereby states that since the present application 09/996,023 and copending application 09/572,553 (now US patent 6,503,949) were, at the

time the invention of application 09/996,023 was made, commonly owned by Novo Nordisk A/S and Agouron Pharmaceuticals Inc., copending application 09/572,553 (now US patent 6,503,949) is disqualified from being used in a rejection under 35 U.S.C. 103(a) against application 09/996,023.

The evidence supporting common ownership of application 09/996,023 and copending application 09/572,553 is the Assignment at Reel 012657/Frame 0626 in application 09/996,023 and the Assignment at Reel 011657/Frame 0129 in the application 09/572,553 that issued as US patent 6,503,949.

In view of the above statement by the undersigned and the evidence of common ownership, withdrawal of the obviousness rejection is respectfully requested.

In view of the above, it is respectfully submitted that all pending claims are in condition for allowance.

Early action to that end is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: March 11, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540 (609) 987-5800

23650

PATENT TRADEMARK OFFICE

"Marked-Up" Copy Of Amendments To The Claims

- 4. (Amended) A compound which is selected from
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethyl-5-fluorophenyl)ureidomethyl]benzoylamino}-propionic acid.
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethyl-5-fluorophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethyl-5-cyanophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-chlorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethyl-5-cyanophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-chlorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex1-enylphenyl)-3-(3-chlorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylsulfonyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylsulfonyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylsulfonylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylsulfonyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylsulfonylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-tert-butylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-tert-butylphenyl)ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-tert-butylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-hydroxymethyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-hydroxymethyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-hydroxymethyl-4-trifluoromethoxyphenyl)ureido-methyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylthiophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylthiophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylthiophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-iodophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-iodophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-iodophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-[methylsulfony] <u>methylsulfonyl</u>-4-butoxyphenyl)ureido-methyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-[methylsulfony] <u>methylsulfonyl</u> -4-butoxyphenyl)ureido-methyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-[methylsulfony] <u>methylsulfonyl</u> -4-butoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(2-butyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)ureido-methyl]benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2-butyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-isopropyl-[1,2,4]oxadiazol-5-ylphenyl)ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-isopropyl-[1,2,4]oxadiazol-5-ylphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[3-[1(S)-(4-chlorophenyl)ethyl]-1-(4-cyclohexylphenyl)ureidomethylbenzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-isopropyl-[1,2,4]oxadiazol-5-ylphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[3-[1(S)-(4-chlorophenyl)ethyl]-1-(4-cyclohexylcyclohexyl)ureidomethylbenzoylamino}-propionic acid,
- 3-{4-[3-[1(S)-(4-chlorophenyl)ethyl]-1-(4-cyclohex-1-enylphenyl)ureidomethylbenzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-ethylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-ethylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-ethylphenylsulfamoylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylphenylsulfamoyl-4-methylphenyl)ureidomethyl]-benzoylamino}propionic acid,
- $3-\{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylphenylsulfamoyl-4-methylphenyl)ure idomethyl]-benzoylamino\} propionic acid \underline{,}$
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2-isopropyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)-ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylphenylsulfamoyl-4-methylphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(2-isopropyl-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)ureidomethyl]benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-ethylphenylsulfamoyl-4-methylphenyl)ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-ethylphenylsulfamoyl-4-methylphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(2-[2,2,2-trifluoroethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)-ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2-[2,2,2-trifluoroethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(2-[2,2,2-trifluoroethyl]-1,3-dioxo-2,3-dihydro-1*H*-isoindol-5-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(5-methylsulfonylthiophen-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-methylsulfonylthiophen-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylcyclohexyl)-3-(5-methylsulfonylthiophen-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[3-biphenyl-2-ylmethyl-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[3-biphenyl-2-ylmethyl-1-(4-cyclohex-1-enylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-trifluoromethyl-4-chlorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(2,2,4,4-tetrafluorobenzo[1,3]dioxin-6-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethyl-4-chlorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(2,2,4,4-tetrafluorobenzo[1,3]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2,2,4,4-tetrafluorobenzo[1,3]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3,3,4,4-tetrafluorobenzo[1,4]dioxin-6-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3,3,4,4-tetrafluorobenzo[1,4]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-benzothiazol-2-yl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3,3,4,4-tetrafluorobenzo[1,4]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-fluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-fluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-fluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-methylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-ethylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexyphenyl)-3-(3-ethylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-ethylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-nitrophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-nitro-4-methylphenyl)ureidomethyl]benzoylamino}-propionic acid.
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-nitrophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-nitro-4-methylphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-nitro-4-methylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-cyanophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-cyanophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-phenoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-cyanophenyl)ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-phenoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-phenoxyphenyl)ureidomethyl]benzoylamino}propionic acid.

- 3-{4-[1-(4-cyclohexylphenyl)-3-(3,5-difluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3,5-difluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3,5-difluorophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(6-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5,7-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5,7-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(4,6-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-fluoro-7-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(4,6-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethyl-7-methoxybenzothiazol-2-yl)ureido-methyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-fluoro-7-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(4-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(4-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(7-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(7-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohexylphenyl)-3-(4-fluro-6-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(4-fluro-6-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5,6-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-bromobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-bromo-7-fluorobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-bromo-7-fluorobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-bromobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethylbenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5,7-bis(trifluoromethyl)benzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethylbenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5,7-bis(trifluoromethyl)benzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- $3-\{4-[1-(4-cyclohexylphenyl)-3-(6,6,8,8-tetrafluoro-6H-dioxino[5,4-f]benzothiazol-2-yl)ureidomethyl]benzoylamino\}propionic acid.$
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6,6,8,8-tetrafluoro-6*H*-dioxino[5,4-f]benzothiazol-2-yl)-ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5,6-(tetrafluoroethylenedioxo)benzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-fluoro-6-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-fluoro-6-trifluoromethylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(6,7-(tetrafluoroethylenedioxo)benzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6,7-(tetrafluoroethylenedioxo)benzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6-trifluoromethylthiobenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(6-trifluoromethylthiobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(6,7-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6,7-dichlorobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethylthiobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethyl-6-cyanobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethyl-6-cyanobenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethyl-7-methylbenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethyl-7-methylbenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethyl-7-cyanobenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethyl-7-cyanobenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluoromethyl-6-bromobenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- $3-\{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-trifluoromethyl-6-bromobenzothiazol-2-yl)ure idomethyl] benzoylamino\} propionic acid,$
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(5-tert-butylbenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-tert-butylbenzothiazol-2-yl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(5-trifluromethyl-7-methoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylsulfonyl-4-methylphenyl)ureidomethyl]benzoylamino}-propionic acid,

- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylsulfonyl-4-methylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-ethylthiophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-ethylthiophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-acetylphenyl)ureidomethyl]benzoylamino)propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-acetylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-chloro-4-cyanophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-chloro-4-cyanophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-chloro-4-bromophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-chloro-4-bromophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)ureido-methyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2-methyl-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl)ureido-methyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-benzooxazol-2-yl-4-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-benzooxazol-2-yl-4-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-(2-methyl-2*H*-tetrazol-5-yl)phenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-(2-methyl-2*H*-tetrazol-5-yl)phenyl)ureidomethyl]-benzoylamino}propionic acid, and
- 3-{4-[3-(3-cyano-5-trifluoromethylphenyl)-1-(4-cyclohex-1-enylphenyl)ureidomethyl]benzoylamino}propionic acid
- or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.

- 5. (Amended) A compound which is selected from
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethyl-5-fluorophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethyl-5-cyanophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylsulfonyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-hydroxymethyl-4-trifluoromethoxyphenyl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-hydroxymethyl-4-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3-methylthiophenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-methylthiophenyl)ureidomethyl]benzoylamino}-propionic acid,
- 3-{4-[3-[1(S)-(4-Chlorophenyl)ethyl]-1-(4-cyclohexylphenyl)ureidomethylbenzoylamino}-propionic acid,
- 3-{4-[3-biphenyl-2-ylmethyl-1-(4-cyclohexylphenyl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(2,2,4,4-tetrafluorobenzo[1,3]dioxin-6-yl)ureidomethyl]benzoylamino}propionic acid.
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(2,2,4,4-tetrafluorobenzo[1,3]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(3,3,4,4-tetrafluorobenzo[1,4]dioxin-6-yl)ureidomethyl]benzoylamino}propionic acid,

- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3,3,4,4-tetrafluorobenzo[1,4]dioxin-6-yl)ureidomethyl]-benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohexylphenyl)-3-(6-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]benzoylamino}propionic acid,
- 3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(6-trifluoromethoxybenzothiazol-2-yl)ureidomethyl]-benzoylamino}propionic acid, and
- 3-{4-[3-(3-cyano-5-trifluoromethylphenyl)-1-(4-cyclohex-1-enylphenyl)ureidomethyl]benzoylamino}propionic acid
- or any optical or geometric isomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof.
- 6. (Amended) A pharmaceutical composition according to claim 4 in unit dosage form, said composition comprising from about 0.05 mg to about 1000 mg of [the] <u>said</u> compound [according to claim 1].
- 35. (Amended) A pharmaceutical composition according to claim 4 in unit dosage form, said composition comprising from about 0.1 mg to about 500 mg of [the] <u>said</u> compound [according to claim 1].
- 36. (Amended) A pharmaceutical composition according to claim 4 in unit dosage form, said composition comprising from about 0.5 mg to about 200 mg of [the] <u>said</u> compound [according to claim 1].